We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

6 hedge funds and large institutions have $464K invested in Artelo Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.43% more ownership

Funds ownership: 3.31% → 4.74% (+1.4%)

5% more capital invested

Capital invested by funds: $443K → $464K (+$21.2K)

50% less funds holding

Funds holding: 12 → 6 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
6
Holders Change
-6
Holders Change %
-50%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$157K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$114K
3
Two Sigma Investments
Two Sigma Investments
New York
+$47.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.35K
5
UBS Group
UBS Group
Switzerland
+$3.62K

Top Sellers

Rank Fund Capital Flow
1
SCA
Snowden Capital Advisors
New York
-$34K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$27K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$25K
4
Northern Trust
Northern Trust
Illinois
-$20K
5
VF
Virtu Financial
New York
-$20K

ARTL Hedge Fund Activity: Q3 2022 in Review

6 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2022, worth a combined $464K — up 4.8% from $443K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ARTL and 2 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $157K. The largest seller was Snowden Capital Advisors, exiting entirely with an estimated $34K sold.

  • 6 institutional investors held Artelo Biosciences (ARTL) as of Q3 2022, down from 12 in Q2 2022.
  • Funds reported $464K of Artelo Biosciences stock for Q3 2022, up 4.8% quarter-over-quarter.
  • 2 funds opened new Artelo Biosciences positions in Q3 2022 and 8 closed out, a net change of -6 holders.
  • The largest Artelo Biosciences buyer in Q3 2022 was Two Sigma Advisers, an estimated $157K added.
  • The largest Artelo Biosciences seller in Q3 2022 was Snowden Capital Advisors, an estimated $34K sold.

Based on aggregated 13F filings for Q3 2022.